Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis

Table 1 Basic characteristics of included studies

Ref.	Sample size	Gender (male)	Age (median, range), years	Country	Stage	Number of colon carcinoma	Treatment	Tumor type	Threshold	Endpoints	NOS
Cintin et al[20], 1999	603	355	69 (33-91)	Denmark	Duke A-D	355	Surgery	CRC	247 ug/L (upper 95th percentile)	OS	7
Cintin et al[21], 2002	324	192	68 (37-90)	Denmark	Duke A-D	197	Surgery	CRC	247 ug/L (upper 95th percentile)	OS, PFS	7
Liu et al[24], 2014	86	48	60 (38-76)	China	TNMI I-IV	34	Surgery	CRC	216 ng/mL (median)	PFS	6
Tarpgaard et al[27], 2014	510	301	NR	Denmark	TNM IV	302	Non-surgery	CRC	155 ug/L (upper 95th percentile)	OS, PFS	7
Fuksiewicz et al[22], 2018	83	59	65 (25-82)	Poland	TNM I-III	NR	Surgery	RC	44.6 pg/mL (upper 95th percentile)	OS, PFS	6
Hermunen et al[23], 2020	147	75	60 (31-76)	Finland	TNM II-IV	87	Surgery	CRC	70.7 ng/mL (maximum Youden’s index)	OS, PFS	7
Peltonen et al[26], 2020	441	260	64.9 (33-84)	Denmark	TNM IV	258	Surgery (liver resection)	CRC	34.8 ng/mL (upper 95th percentile)	OS, PFS
Oh et al[25], 2021	265	134	NR	Korea	TNM I-IV	NR	Surgery	CRC	Positive in tumor cells	OS, PFS	7
Yang et al[28], 2021	86	56	60.12 ± 7.32 (mean ± SD)	China	TNMI I-IV	86	Surgery	CC	Positive in tumor cells	OS	7

TNM: Tumor-node-metastasis; CRC: Colorectal cancer; RC: Rectal cancer; CC: Colon cancer; OS: Overall survival; PFS: Progression-free survival; NOS: Newcastle-Ottawa scale; NR: Not reported.